4d Pharma PLC Participation in Chardan Conference
16 March 2020 - 6:00PM
RNS Non-Regulatory
TIDMDDDD
4d Pharma PLC
16 March 2020
4D pharma plc
(the "Company" or "4D")
4D announces participation in Chardan Microbiome Medicines
Summit
LEEDS, UK -- 4D pharma plc (AIM: DDDD), a pharmaceutical company
leading the development of Live Biotherapeutics, today announces
its participation in the 2nd Annual Chardan Capital Markets LLC
Microbiome Medicines Summit on 16 March 2020.
Duncan Peyton, 4D's Chief Executive Officer, and Alex Stevenson,
4D's Chief Scientific Officer, will be delivering a virtual
presentation on 4D's clinical progress in oncology and provide an
update on upcoming timelines and catalysts for 2020.
A recording of the presentation will be made available here at
13:15 GMT:
https://www.4dpharmaplc.com/en/investors/reports-presentations
For further information please contact:
4D
Duncan Peyton, Chief Executive Officer + 44 (0)113 895 0130
Investor Relations ir@4dpharmaplc.com
N+1 Singer - Nominated Adviser and Joint Broker +44 (0) 20 7496
3000
Aubrey Powell / Justin McKeegan / Alex Bond (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332
2500
Dominic Wilson / Phil Walker
About 4D
Founded in February 2014, 4D is a world leader in the
development of Live Biotherapeutics, a novel and emerging class of
drug, defined by the FDA as biological products that contain a live
organism, such as a bacterium, that is applicable to the
prevention, treatment or cure of a disease. 4D has developed a
proprietary platform, MicroRx(R), that rationally identifies Live
Biotherapeutics based on a deep understanding of function and
mechanism. 4D's Live Biotherapeutic products are orally delivered
single strains of bacteria originally isolated from the gut
microbiome of healthy human donors. The Company currently has five
clinical studies in progress, namely a Phase II clinical study of
Blautix in irritable bowel syndrome (IBS), a Phase I/II study of
MRx0518 in combination with KEYTRUDA(R) (pembrolizumab) in solid
tumours, a Phase I study of MRx0518 in a neoadjuvant setting for
patients with solid tumours, a Phase I study of MRx0518 in
combination with preoperative radiotherapy for pancreatic cancer,
and a Phase I/II study of MRx-4DP0004 in asthma. Preclinical-stage
programmes include candidates for oncology, CNS diseases such as
Parkinson's disease and other neurodegenerative conditions, and
autoimmune diseases. The company has a research collaboration with
MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA,
to discover and develop Live Biotherapeutics for vaccines.
For more information, refer to https://www.4dpharmaplc.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAGPUQPWUPUGPW
(END) Dow Jones Newswires
March 16, 2020 03:00 ET (07:00 GMT)
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2024 to May 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From May 2023 to May 2024